Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Repligen Corp (RGEN)
NASDAQ:RGEN
RGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$113.50 - $203.13
Previous CloseN/A
Volume111.19K
Average Volume (3M)574.50K
Market Cap
$8.13B
Enterprise Value$8.22B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Feb 20, 2025EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding56,026,726
10 Day Avg. Volume538,858
30 Day Avg. Volume574,498
Standard Deviation0.13
R-Squared0.17
Alpha0.00415
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.20
Price to Cash Flow (P/CF)41.20
P/FCF Ratio48.20
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit26.63
Enterprise Value/Ebitda94.23
Forecast
1Y Price Target
$187.57Price Target Upside15.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Guidance And PerformanceA solid fourth quarter performance and an optimistic 2025 guidance have provided a boost for the stock.
Product InnovationRepligen launched AVIPure dsRNA resin which is the first affinity resin to remove double stranded RNA addressing a key bottleneck for mRNA therapeutics and vaccines.
Bears Say
Revenue DeclineThe revenue from China saw a significant decline, which was over 50% year-over-year.
---
Ownership Overview
0.70% Insiders
36.10% Mutual Funds
27.39% Other Institutional Investors
14.67% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RGEN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $113.50 and its highest was $203.13 in the past 12 months.
What is Repligen Corp’s market cap?
Repligen Corp’s market cap is $8.13B.
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Feb 20, 2025 which is yesterday.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Nov 12, 2024. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.335 by $0.095.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is 0.41.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 56,026,726 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of $0.43 in its last earnings report, beating expectations of $0.335. Following the earnings report the stock price went up 7.921%.
Which hedge fund is a major shareholder of Repligen Corp?
Currently, no hedge funds are holding shares in RGEN
---
Repligen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$187.57 (15.31% Upside)
$187.57 (15.31% Upside)
Blogger Sentiment
Neutral
RGEN Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 15.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.67%
12-Months-Change
Fundamentals
Return on Equity
-0.41%
Trailing 12-Months
Asset Growth
12.21%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
---
RGEN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Repligen's earnings call highlighted strong growth in the CDMO and equipment segments, successful execution of strategic priorities, and positive outlook for 2025. However, challenges in China and the protein segment, along with restructuring charges, were notable lowlights. Despite these challenges, the positive aspects, including strong revenue growth and strategic achievements, outweigh the negatives.Read More>---
RGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
---
RGEN Stock 12 Month Forecast
Average Price Target
$187.57
▲(15.31% Upside)
Technical Analysis
Best Analysts Covering RGEN
1 Year
1 Year Success Rate
13/20 ratings generated profit
1 Year Average Return
+24.55%
reiterated a buy rating 3 months ago
Copying Daniel Arias's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +24.55% per trade.
---